Technopolis Moscow has begun the production of a new therapy for dementia in Alzheimer’s disease, available in the form of tablets in four dosages. This is reported on the official website of the mayor of Moscow.
“The new drug was developed by a Russian pharmaceutical company and is produced at the site of the capital’s Special Economic Zone. The product will be delivered to pharmacies in Moscow in April 2022,” said Vladimir Efimov, Vice Mayor of the city.
Its uniqueness lies in the combination of two molecules complementing each other’s action in one dosage form.
As noted, the cluster of medical technologies, equipment, and biopharmaceuticals in the SEZ Technopolis Moscow currently includes about 30 enterprises that make “a significant contribution to the development of modern medicine and provide the Russian capital and regions with drugs and medical devices.”
“The SEZ of the capital has become a center of attraction for innovative companies with great technological potential. About 20 enterprises today have the status of a resident in the SEZ. They produce therapies for the treatment of oncological, endocrine, and immune diseases. The production of a Russian drug at the facilities of Technopolis Moscow clearly serves as an example of the domestic pharma’s readiness to create and manufacture innovative products,” Vladislav Ovchinsky, Head of the Moscow Investment and Industrial Policy Department, said.
Over the past year, six medicine-oriented enterprises have joined the community of Moscow’s SEZ.
As it became known earlier, 80 jobs were opened at the pharmaceutical enterprises of Technopolis Moscow.
